EA201691452A1 - Композиции для применения в лечении аллергических состояний - Google Patents

Композиции для применения в лечении аллергических состояний

Info

Publication number
EA201691452A1
EA201691452A1 EA201691452A EA201691452A EA201691452A1 EA 201691452 A1 EA201691452 A1 EA 201691452A1 EA 201691452 A EA201691452 A EA 201691452A EA 201691452 A EA201691452 A EA 201691452A EA 201691452 A1 EA201691452 A1 EA 201691452A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
treatment
application
allergic states
allergic
Prior art date
Application number
EA201691452A
Other languages
English (en)
Inventor
Стивен Г. Рид
Кристофер Х. Клегг
Кристофер Арендт
Александра Кропотова
Курт Стоуэкли
Original Assignee
Иммьюн Дизайн Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691452(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Иммьюн Дизайн Корп. filed Critical Иммьюн Дизайн Корп.
Publication of EA201691452A1 publication Critical patent/EA201691452A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

В данном документе представлены композиции и способы для лечения аллергических состояний введением адъювантной композиции с аллергеном или без аллергена.
EA201691452A 2014-01-21 2015-01-20 Композиции для применения в лечении аллергических состояний EA201691452A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929780P 2014-01-21 2014-01-21
PCT/US2015/012003 WO2015112485A1 (en) 2014-01-21 2015-01-20 Compositions for use in the treatment of allergic conditions

Publications (1)

Publication Number Publication Date
EA201691452A1 true EA201691452A1 (ru) 2016-12-30

Family

ID=52462439

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691452A EA201691452A1 (ru) 2014-01-21 2015-01-20 Композиции для применения в лечении аллергических состояний

Country Status (19)

Country Link
US (1) US20160030459A1 (ru)
EP (1) EP3096764A1 (ru)
JP (1) JP2017502977A (ru)
KR (1) KR20160105813A (ru)
CN (1) CN105960241A (ru)
AU (1) AU2015209575A1 (ru)
BR (1) BR112016016672A2 (ru)
CA (1) CA2935722A1 (ru)
CL (1) CL2016001843A1 (ru)
CR (1) CR20160369A (ru)
EA (1) EA201691452A1 (ru)
HK (1) HK1225994A1 (ru)
IL (1) IL246587A0 (ru)
MA (1) MA39228A1 (ru)
MX (1) MX2016009464A (ru)
PH (1) PH12016501434A1 (ru)
SG (1) SG11201605883UA (ru)
TW (1) TW201620524A (ru)
WO (1) WO2015112485A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
US20190256566A1 (en) * 2016-06-16 2019-08-22 Hoyu Co., Ltd. Fish allergy antigen
US11173113B2 (en) 2017-12-06 2021-11-16 Prollergy Corporation Composition and method for reducing allergic response
AU2021258392A1 (en) 2020-04-19 2022-12-15 Ludwig ENGLMEIER Prophylaxis and treatment of coronavirus infection

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
JPH07504683A (ja) 1992-07-08 1995-05-25 シェリング・コーポレーション Ｇｍ−ｃｓｆのワクチンアジュバントとしての利用
EP0887867B1 (en) 1993-11-02 2004-04-21 Matsushita Electric Industrial Co., Ltd Semiconductor device comprising an aggregate of semiconductor micro-needles
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE9319879U1 (de) 1993-12-23 1994-03-17 Inventa Ag Sequentiell Coextrudierte Kühlflüssigkeitsleitung
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6685699B1 (en) 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
JP4162813B2 (ja) 1999-10-28 2008-10-08 久光製薬株式会社 イオントフォレーシス装置
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TR201807756T4 (tr) * 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
CA2698668A1 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
MX2011012836A (es) * 2009-06-05 2012-04-20 Infectious Disease Res Inst Adyuvantes sinteticos de glucopiranosil-lipido.

Also Published As

Publication number Publication date
WO2015112485A1 (en) 2015-07-30
CA2935722A1 (en) 2015-07-30
US20160030459A1 (en) 2016-02-04
HK1225994A1 (zh) 2017-09-22
MX2016009464A (es) 2017-01-16
CR20160369A (es) 2016-10-05
SG11201605883UA (en) 2016-08-30
PH12016501434A1 (en) 2016-09-14
CN105960241A (zh) 2016-09-21
CL2016001843A1 (es) 2017-04-28
EP3096764A1 (en) 2016-11-30
IL246587A0 (en) 2016-08-31
AU2015209575A1 (en) 2016-07-21
JP2017502977A (ja) 2017-01-26
KR20160105813A (ko) 2016-09-07
MA39228A1 (fr) 2017-06-30
TW201620524A (zh) 2016-06-16
BR112016016672A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
EA201892386A1 (ru) Химерные нейротоксины
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
BR112017006664A2 (pt) terapias de combinação
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
EA201691582A1 (ru) Новые фармацевтические препараты
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201592203A1 (ru) Способы лечения таупатии
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний